Print page Resize text Change font-size Change font-size Change font-size High contrast

Home > Standards & Guidances > Methodological Guide

ENCePP Guide on Methodological Standards in Pharmacoepidemiology


Chapter 8: Dissemination and communication of study results

Aspects of dissemination and communication of study results include, but are not limited to, reports to health authorities and study sponsors, presentations in scientific fora, scientific publications, patient focused communications and websites.


The Declaration of Helsinki provides overarching guidance on the registration, publication and dissemination of research results. Every research study involving human subjects must be registered in a publicly accessible database before recruitment of the first subject. A means to achieve this with pharmacoepidemiology and pharmacovigilance studies is through registration of protocols and reports of studies in the European Union electronic Register of Post-Authorisation Studies (EU PAS Register), ideally before they start, and protocols and study results should be made public. This is compulsory only for study imposed by regulators.


Authorship should conform to the guidelines established by the International Committee of Medical Journal Editors (ICJME) ‘Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly work in Medical Journals’.


Important specific points relating to reporting of study results that are common to the various guidelines cited below are that:

  • Sources of research funding should always be disclosed whether in oral or written presentation of results.

  • A dissemination and communication strategy should be pre-defined as part of the funding contract for a given study.


  • All results with a scientific or public health impact must be reported to relevant authorities and made publicly available without undue delay.


  • Quantitative measures of association should be reported rather than just results of statistical testing.


The ISPE GPP contain a section on communication (section V) which includes a statement that there is an ethical obligation to disseminate findings of potential scientific or public health importance and that research sponsors (government agencies, private sector, etc.) shall be informed of study results in a manner that complies with local regulatory requirements. The European Medicines Agency (EMA) Guidance for the format and content of the protocol of non-interventional post-authorisation safety studies states that plans for disseminating and communicating study results are to be described as part of study planning activities.


The EMA Guidance for the format and content of the final study report of non-interventional post-authorisation safety studies (PASS) provides a template for final study reports that may be applied to any non-interventional PASS, including meta-analyses and systematic reviews. The FDA’s Best Practices for Conducting and Reporting Pharmacoepidemiologic Safety Studies Using Electronic Health Care Data Sets includes a description of all the elements that should be addressed and included in the final study report of such studies.


The Enhancing the Quality and Transparency of Health Research (EQUATOR) network is an international initiative that aims to enhance the reliability and value of the published health research literature. A catalogue of reporting guidelines for health research (Eur J Clin Invest 2010;40(1):35-53) presents a collection of tools and guidelines available on the EQUATOR website relating to resources, education and training to facilitate good research reporting and the development, dissemination and implementation of robust reporting guidelines to increase the accuracy and transparency of health research reporting.


The Strengthening the Reporting of Observational studies in Epidemiology (STROBE) Statement Guidelines for reporting observational studies has established recommendations for improving the quality of reporting of observational studies and seeks to ensure a clear presentation of what was planned, done, and found. Of note, the aim of these guidelines was not to require the reporting of observational research in a rigid format, but to address what should be the essential information contained in a publication on an observational study.


The REporting of studies Conducted using Observational Routinely-collected health Data (RECORD) Statement (PLoS Med. 2015;12(10):e1001885) was created as an extension to the STROBE statement to address reporting items specific to observational studies using routinely collected health data. RECORD makes additional recommendations on the reporting of methods of selection of study populations, exposures, outcomes and covariates (including codes or algorithms used), whether validation has been conducted, the level of access to databases used, and data linkages that were required to conduct the study. The RECORD-PE statement (BMJ 2018;363:k3532) aims to extend existing STROBE and RECORD guidelines providing guidance for the reporting of pharmacoepidemiological studies using routinely collected data.


The joint ISPE‐ISPOR Special Task Force on Real World Evidence in Health Care Decision Making developed a guidance on Reporting to Improve Reproducibility and Facilitate Validity Assessment for Healthcare Database Studies (Pharmacoepidemiol Drug Saf. 2017;26(9):1018-32), with the objective “to catalogue scientific decisions underpinning study execution that should be reported to facilitate replication and enable assessment of validity of studies conducted in large healthcare databases.” A key recommendation is that “A substantial improvement in reproducibility, rigor and confidence in real world evidence generated from healthcare databases could be achieved with greater transparency about operational study parameters used to create analytic datasets from longitudinal healthcare databases”.


The Good ReseArch for Comparative Effectiveness (GRACE) guidance includes recommendations on reporting comparative effectiveness studies. The STARD guidelines (BMJ Open 2016;14;6(11):e012799) focus on reporting diagnostic accuracy studies.


The Meta-analysis of Observational Studies in Epidemiology (MOOSE) group (JAMA 2000;283(15):2008-15) has developed a consensus statement and recommendations for reporting meta-analyses of observational studies. It is equivalent to the STROBE Statement and the Consolidated Standards of Reporting Trials Consolidated Standards for Reporting Trials (CONSORT) 2010 Statement for RCTs, in focusing primarily on communication and list the minimum requirements for adequate reporting. The authors recommend a broad inclusion of studies and conduct of post-hoc sensitivity testing on the dependence of the results on factors such as quality of underlying papers, design, accounting for confounders, etc. The authors comment on the particular problems in merging observational studies with highly variable sets of confounders that were or were not controlled for, but they do not suggest any solution or give any references to possible ways to address it. As pragmatic trials increase in our field, another CONSORT extension focused on this type of studies, Improving the reporting of pragmatic trials: an extension of the CONSORT Statement (BMJ 2008;337:a2390) might be also relevant.


The Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement (BMJ 2009;339:b2535) is an evidence-based minimum set of items for reporting in systematic reviews and meta-analyses. While focused on randomised trials, PRISMA can also be used as a basis for reporting systematic reviews of other types of research, particularly evaluations of interventions. PRISMA may also be useful for critical appraisal of published systematic reviews, although it is not designed as a quality assessment instrument.


Module VI of the Guideline on good pharmacovigilance practices (GVP) addresses the legal requirements which are applicable regards submission of individual reports of suspected adverse reactions associated with medicinal products authorised in the European Union. The Guidelines for Submitting Adverse Event Reports for Publication (Pharmacoepidemiol Drug Saf 2007;16(5): 581–7) also list key elements that have to be included when publishing a report of one or more adverse events.  These guidelines have been endorsed by the International Society for Pharmacoepidemiology (ISPE) and the International Society of Pharmacovigilance (ISoP) and are available on their web sites.


Several of the guidelines listed above include recommendations on the minimum information to be provided on data sources used in pharmacoepidemiology. The name, type, content and validity of the database and the original reasons why the data were collected should be reported with the extent of access, data cleaning methods and details of linkage (see The REporting of studies Conducted using Observational Routinely-collected health Data (RECORD) Statement. PLoS Med. 2015;12(10):e1001885). To allow reproducibility reporting of extraction date, data version, data sampling strategy and the years of source data used for the study are required, as described in Reporting to Improve Reproducibility and Facilitate Validity Assessment for Healthcare Database Studies, V1.0. (Pharmacoepidemiol Drug Saf. 2017;26(9):1018-1032).


Additional guidance on reporting of study results is provided in the ENCePP Checklist for Study Protocols and Code of Conduct and the IEA GEP guideline that are reviewed elsewhere in this Guide.



« Back to main table of contents